Infliximab therapy in Behçet's uveitis

• DOI: 10.1016/j.jfo.2022.04.009
• Publication Date: 2022-09-20T12:45:06Z
• Authors: F. Alizadegan; O. Yalcinbayir; G. Ucan Gunduz; Y. Pehlivan
• Keywords: Refractory (planetary science)

To evaluate the efficacy of infliximab (IFX) therapy in patients with Behçet's uveitis (BU) refractory to conventional immunomodulatory treatment (IMT).This study, trial registration number TCTR20200806007, included cases of BU with a minimum of 18 months follow-up on IFX treatment. Demographic characteristics, ophthalmological examination findings, control of ocular inflammation with IFX, response to treatment and the rate of clinical remission were analyzed in this study.Sixty-two eyes of 35 patients on IFX therapy were included in the study. The mean follow-up was 49.5±25.9months. The mean frequency of recurrences during the IMT was 1.47±0.78 (attacks/year), decreasing to 0.31±0.40 (attacks/year) with IFX (P<0.001). Visual acuity improved significantly in the 1st month of IFX treatment (P=0.026). Partial response to treatment was achieved in 91.4% of cases.IFX is a safe and effective treatment in cases of BU refractory to conventional IMT.